Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Parkinson's Disease
Interventions
DRUG

Coenzyme Q10 Nanodispersion (Nanoquinone)

DRUG

Placebo

Trial Locations (13)

13353

Department of Neurology, Charite Berlin, Berlin

21339

Department of Neurology, Klinikum Lueneburg, Lüneburg

32657

Department of Nuerology, Klinikum Lippe, Lemgo

35039

Department of Neurology, University of Marburg, Marburg

44791

Department of Neurology, Ruhr-University of Bochum, Bochum

45359

Department of Neurology, Klinikum Essen-Borbeck, Essen

58091

Department of Neurology, Klinik Ambrock, Hagen

65191

Department of Neurology, Deutsche Klinik fuer Diagnostik, Wiesbaden

66421

Department of Neurology, University of Homburg, Homburg

89081

Department of Neurology, University of Ulm, Ulm

89335

Department of Neurology, Fachklinik Ichenhausen, Ichenhausen

97422

Department of Neurology, Leopoldina Krankenhaus, Schweinfurt

01307

Department of Neurology, Technical University of Dresden, Dresden

All Listed Sponsors
collaborator

Deutsche Parkinson-Vereinigung e.V.

UNKNOWN

collaborator

MSE Pharmazeutika GmbH, Bad Homburg

UNKNOWN

lead

Technische Universität Dresden

OTHER

NCT00180037 - Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease | Biotech Hunter | Biotech Hunter